Rigontec raises $12M for immuno-oncology; bluebird kicks off sickle cell study;

@FierceBiotech: Novartis joins an Atlas syndicate to back cancer drug upstart Raze. News | Follow @FierceBiotech

@JohnCFierce: Pharma VCs cluster behind a brainchild of UK biotech pioneer Sir Greg Winter. Report | Follow @JohnCFierce

@DamianFierce: NPR talks CRISPR with Berkeley's Jennifer Doudna, who happens to be a founder of Fierce 15 winner. More | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> Rigontec, a German biotech at work on immunotherapies for cancer, raised a €9.5 million ($12 million) A round, led by Wellington Partners and Boehringer Ingelheim Venture Fund. More

> Bluebird bio ($BLUE) has treated its first patient in a Phase I/II study of a gene therapy for sickle cell disease, a clinical first. News

> Gilead Sciences' ($GILD) announcement of a $94,500 price tag on the new hepatitis C treatment Harvoni has spurred speculation that AbbVie ($ABBV), soon to launch a competing product, may mount a price war. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Steris to buy Synergy for $1.9B in another med tech tax inversion deal. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: PAD patients gain another treatment option as the FDA approves its first drug-coated balloon. Story | Follow @VarunSaxena2

@EmilyWFierce: The top 10 most expensive drugs of 2013 range from $100K to upwards of $500K. Find out which ones made the list here. FiercePharma feature | Follow @EmilyWFierce

@MichaelGFierce: With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. FierceDrugDelivery story | Follow @MichaelGFierce

> AstraZeneca's $2B cancer contender lines up for EU scrutiny. More

> Stanford engineers develop pressure sensor that could lead to advances in prosthetics, medicine. Story

> Eye care Dx maker RPS receives $28M in debt financing from OrbiMed. Article

Pharma News

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Artes, InstrAction, Q-Biologicals team up on virus-like particle (VLP) platform for vet vax. FierceAnimalHealth story | Follow @EricPFierce

@CarlyHFierce: Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Could Gilead's $95K nod trigger creative payment ideas? Ask J&J and AbbVie. More

> J&J beats the Street for Q3, thanks to surging sales of standout drugs. Report

> Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article

Biotech Research News

> Out-of-control neural stem cell growth may play part in autism. News

> HIV spikes reveal clues for vaccine development. Report

> Amicus drug improves Parkinson's symptoms in mice. Story

> Beta cells produced from stem cells could treat Type 1 diabetes. More

> Tetraphase antibiotic candidate kills gram-negative, resistant bacteria. Article

Pharma Manufacturing News

> Indian drugmakers scramble to prevent shortages of HIV/AIDS meds. Item

> FDA chastises Sun for weak follow-through on drug recalls. News

> Sources: Ranbaxy's key U.S. operations losing top dogs. More

> Mapp, HHS scrambling to find ways to supercharge production of Ebola drug. Story

> GSK adds jobs at North Carolina plant, expecting new drugs to take off. Article

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.